March 30, 2008 – Data showing strong clinical efficacy for Medtronic’s Endeavor® drug-eluting stent were presented today at the American College of Cardiology meeting. Entitled “One-Year Clinical and Angiographic Results in Diabetics from ENDEAVOR IV: A Randomized Comparison of the Endeavor Drug Eluting Stent System Versus Taxus in de novo Native Coronary Lesions” (2803-8) – the presentation featured an analysis of 477 diabetic patients from the ENDEAVOR IV clinical study. ENDEAVOR IV is an ongoing head-to-head comparison of the Endeavor and Taxus stents in 1,548 patients... Medtronic's Press Release -
Monday, April 14, 2008
12-Month Data from Endeavor IV Show Strong Clinical Efficacy of Medtronic’s Drug-Eluting Stent Across All Patient Groups
March 30, 2008 – Data showing strong clinical efficacy for Medtronic’s Endeavor® drug-eluting stent were presented today at the American College of Cardiology meeting. Entitled “One-Year Clinical and Angiographic Results in Diabetics from ENDEAVOR IV: A Randomized Comparison of the Endeavor Drug Eluting Stent System Versus Taxus in de novo Native Coronary Lesions” (2803-8) – the presentation featured an analysis of 477 diabetic patients from the ENDEAVOR IV clinical study. ENDEAVOR IV is an ongoing head-to-head comparison of the Endeavor and Taxus stents in 1,548 patients... Medtronic's Press Release -
